Glycomimetics Inc (GLYC) 7.43 $GLYC GlycoMimeti
Post# of 273258
Posted On: 09/02/2016 3:17:43 AM
Glycomimetics Inc (GLYC) 7.43 $GLYC
GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack
BusinessWire - Tue Aug 16, 8:15AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of results from a preclinical study that showed its drug candidate GMI-1271 reduced the cellular interactions that often lead to a buildup in inflammatory response and unstable atherosclerotic plaque formation after a heart attack. The study, entitled "E-Selectin Inhibition Mitigates Splenic HSC Activation and Myelopoiesis in Hypercholesterolemic Mice With Myocardial Infarction," was published in the September issue of Arteriosclerosis, Thrombosis, and Vascular Biology.
GLYC: 7.43 (+0.02)
GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference
BusinessWire - Mon Aug 08, 8:15AM CDT
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at Canaccord Genuity 36th Annual Growth Conference in Boston, on Thursday, August 11, 2016 2:30 p.m. ET.
GLYC: 7.43 (+0.02)
Zacks.com featured highlights: GlycoMimetics, Lion Biotechnologies, AMN Healthcare Services, Gibraltar Industries and Coherent
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
Zacks.com featured highlights: GlycoMimetics, Lion Biotechnologies, AMN Healthcare Services, Gibraltar Industries and Coherent
AHS: 35.68 (-0.55), GLYC: 7.43 (+0.02), COHR: 106.11 (+0.93), ROCK: 38.65 (+0.49), LBIO: 7.97 (+0.01)
GlycoMimetics Reports Second Quarter 2016 Results
BusinessWire - Thu Aug 04, 3:15PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the second quarter and six months ended June 30, 2016.
GLYC: 7.43 (+0.02)
7 Stocks with Recent Price Strength for Explosive Returns
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:21AM CDT
Stocks seeing price strength recently have a high chance of carrying the momentum forward.
OSB: 24.62 (+0.55), AHS: 35.68 (-0.55), GLYC: 7.43 (+0.02), LBIO: 7.97 (+0.01), COHR: 106.11 (+0.93), ROCK: 38.65 (+0.49), SBGL: 16.06 (+0.63)
Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:11AM CDT
TrovaGene Inc. (TROV) is expected to release second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), TROV: 4.96 (+0.05), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02)
Inogen (INGN) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:54AM CDT
Inogen Inc. (INGN) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), ANIP: 61.42 (+1.68), INGN: 57.95 (-0.07), GLYC: 7.43 (+0.02)
Pacific Biosciences (PACB) Q2 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:52AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), PACB: 8.30 (-0.03), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02)
Iron Mountain (IRM) to Post Q2 Earnings: What to Expect?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:50AM CDT
Iron Mountain Inc. (IRM), a leading provider of data protection and information management services, is set to release its second-quarter 2016 results on Aug 4.
CTAS: 117.70 (+0.19), IRM: 38.55 (+0.14), GLYC: 7.43 (+0.02), SLCA: 39.76 (+0.51)
Can Cerner (CERN) Spring a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:45PM CDT
Cerner Corporation (CERN) is expected to report second-quarter 2016 results on Aug 2.
ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26), CERN: 65.01 (+0.47)
Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:01PM CDT
Cardinal Health Inc. (CAH) is set to report fourth-quarter fiscal 2016 earnings results on Aug 2.
ANIP: 61.42 (+1.68), CAH: 79.70 (+0.03), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26)
Can PerkinElmer (PKI) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:24AM CDT
PerkinElmer Inc. is expected to report second-quarter 2016 results on Aug 4.
ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), PKI: 53.26 (+0.01), HUM: 176.53 (-2.18)
Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:01AM CDT
Becton, Dickinson and Company (BDX) is set to report third-quarter fiscal 2016 earnings results on Aug 4.
BDX: 177.02 (-0.19), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26)
GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1%
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:00AM CDT
GlycoMimetics, Inc. (GLYC) was a big mover last session, as the company's shares rose over 13% on the day.
GLYC: 7.43 (+0.02)
GlycoMimetics Announces Proposed Public Offering of Common Stock
BusinessWire - Thu Jun 16, 3:01PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by GlycoMimetics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
GLYC: 7.43 (+0.02)
GlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML
BusinessWire - Fri Jun 10, 5:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced data from the Phase 1 portion of its Phase 1/2 clinical trial of its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy, in patients with relapsed/refractory acute myeloid leukemia (AML). Dose escalation is complete and a GMI-1271 dose was identified for Phase 2 testing.
GLYC: 7.43 (+0.02)
GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia
BusinessWire - Mon Jun 06, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) today announced dosing of the first patient with relapsed/refractory acute myeloid leukemia in the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy.
GLYC: 7.43 (+0.02)
GlycoMimetics to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 9:30 a.m. EDT in New York City.
GLYC: 7.43 (+0.02)
Will GlycoMimetics (GLYC) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu May 26, 8:39AM CDT
As of late, it has definitely been a great time to be an investor in GlycoMimetics, Inc. (GLYC).
GLYC: 7.43 (+0.02)
The 3 Best Developmental Stage Biotech Stocks Surging Now
Maher Syed - Zacks Investment Research - Wed May 25, 5:44PM CDT
These Biotech stocks are small now, but they look set to see significant developments in their various drug candidates.
VTAE: 6.84 (-0.07), GLYC: 7.43 (+0.02), DMTX: 5.92 (-0.02)
GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack
BusinessWire - Tue Aug 16, 8:15AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of results from a preclinical study that showed its drug candidate GMI-1271 reduced the cellular interactions that often lead to a buildup in inflammatory response and unstable atherosclerotic plaque formation after a heart attack. The study, entitled "E-Selectin Inhibition Mitigates Splenic HSC Activation and Myelopoiesis in Hypercholesterolemic Mice With Myocardial Infarction," was published in the September issue of Arteriosclerosis, Thrombosis, and Vascular Biology.
GLYC: 7.43 (+0.02)
GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference
BusinessWire - Mon Aug 08, 8:15AM CDT
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at Canaccord Genuity 36th Annual Growth Conference in Boston, on Thursday, August 11, 2016 2:30 p.m. ET.
GLYC: 7.43 (+0.02)
Zacks.com featured highlights: GlycoMimetics, Lion Biotechnologies, AMN Healthcare Services, Gibraltar Industries and Coherent
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
Zacks.com featured highlights: GlycoMimetics, Lion Biotechnologies, AMN Healthcare Services, Gibraltar Industries and Coherent
AHS: 35.68 (-0.55), GLYC: 7.43 (+0.02), COHR: 106.11 (+0.93), ROCK: 38.65 (+0.49), LBIO: 7.97 (+0.01)
GlycoMimetics Reports Second Quarter 2016 Results
BusinessWire - Thu Aug 04, 3:15PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the second quarter and six months ended June 30, 2016.
GLYC: 7.43 (+0.02)
7 Stocks with Recent Price Strength for Explosive Returns
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:21AM CDT
Stocks seeing price strength recently have a high chance of carrying the momentum forward.
OSB: 24.62 (+0.55), AHS: 35.68 (-0.55), GLYC: 7.43 (+0.02), LBIO: 7.97 (+0.01), COHR: 106.11 (+0.93), ROCK: 38.65 (+0.49), SBGL: 16.06 (+0.63)
Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:11AM CDT
TrovaGene Inc. (TROV) is expected to release second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), TROV: 4.96 (+0.05), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02)
Inogen (INGN) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:54AM CDT
Inogen Inc. (INGN) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), ANIP: 61.42 (+1.68), INGN: 57.95 (-0.07), GLYC: 7.43 (+0.02)
Pacific Biosciences (PACB) Q2 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:52AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), PACB: 8.30 (-0.03), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02)
Iron Mountain (IRM) to Post Q2 Earnings: What to Expect?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:50AM CDT
Iron Mountain Inc. (IRM), a leading provider of data protection and information management services, is set to release its second-quarter 2016 results on Aug 4.
CTAS: 117.70 (+0.19), IRM: 38.55 (+0.14), GLYC: 7.43 (+0.02), SLCA: 39.76 (+0.51)
Can Cerner (CERN) Spring a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:45PM CDT
Cerner Corporation (CERN) is expected to report second-quarter 2016 results on Aug 2.
ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26), CERN: 65.01 (+0.47)
Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:01PM CDT
Cardinal Health Inc. (CAH) is set to report fourth-quarter fiscal 2016 earnings results on Aug 2.
ANIP: 61.42 (+1.68), CAH: 79.70 (+0.03), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26)
Can PerkinElmer (PKI) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:24AM CDT
PerkinElmer Inc. is expected to report second-quarter 2016 results on Aug 4.
ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), PKI: 53.26 (+0.01), HUM: 176.53 (-2.18)
Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:01AM CDT
Becton, Dickinson and Company (BDX) is set to report third-quarter fiscal 2016 earnings results on Aug 4.
BDX: 177.02 (-0.19), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26)
GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1%
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:00AM CDT
GlycoMimetics, Inc. (GLYC) was a big mover last session, as the company's shares rose over 13% on the day.
GLYC: 7.43 (+0.02)
GlycoMimetics Announces Proposed Public Offering of Common Stock
BusinessWire - Thu Jun 16, 3:01PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by GlycoMimetics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
GLYC: 7.43 (+0.02)
GlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML
BusinessWire - Fri Jun 10, 5:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced data from the Phase 1 portion of its Phase 1/2 clinical trial of its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy, in patients with relapsed/refractory acute myeloid leukemia (AML). Dose escalation is complete and a GMI-1271 dose was identified for Phase 2 testing.
GLYC: 7.43 (+0.02)
GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia
BusinessWire - Mon Jun 06, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) today announced dosing of the first patient with relapsed/refractory acute myeloid leukemia in the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy.
GLYC: 7.43 (+0.02)
GlycoMimetics to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 9:30 a.m. EDT in New York City.
GLYC: 7.43 (+0.02)
Will GlycoMimetics (GLYC) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu May 26, 8:39AM CDT
As of late, it has definitely been a great time to be an investor in GlycoMimetics, Inc. (GLYC).
GLYC: 7.43 (+0.02)
The 3 Best Developmental Stage Biotech Stocks Surging Now
Maher Syed - Zacks Investment Research - Wed May 25, 5:44PM CDT
These Biotech stocks are small now, but they look set to see significant developments in their various drug candidates.
VTAE: 6.84 (-0.07), GLYC: 7.43 (+0.02), DMTX: 5.92 (-0.02)
(0)
(0)Scroll down for more posts ▼